Table 3. Change in Staphylococcus aureus antimicrobial susceptibility.
| Antibiotics | Lesional skin | Anterior nares | ||||
|---|---|---|---|---|---|---|
| Group A | Group B | p-value | Group A | Group B | p-value | |
| Clindamycin | 52 (81.3) | 100 (94.3) | 0.007 | 50 (87.7) | 21 (91.3) | 1.0 |
| Erythromycin | 38 (59.4) | 97 (91.5) | <0.001 | 36 (63.2) | 21 (91.3) | 0.012 |
| Habekacin | 64 (100.0) | 106 (100.0) | - | 55 (96.5) | 23 (100.0) | 1.0 |
| Oxacillin | 62 (96.9) | 95 (89.6) | 0.134 | 53 (93.0) | 20 (87.0) | 0.218 |
| Gentamicin | 52 (81.3) | 92 (86.8) | 0.331 | 48 (84.2) | 18 (78.3) | 0.530 |
| Penicillin | 9 (14.1) | 22 (20.8) | 0.274 | 8 (14.0) | 6 (26.1) | 0.210 |
| Bactrim | 64 (100.0) | 106 (100.0) | - | 57 (100.0) | 23 (100.0) | - |
| Vancomycin | 64 (100.0) | 106 (100.0) | - | 57 (100.0) | 23 (100.0) | - |
| Ciprofloxacin | - | 105 (99.1) | - | - | 22 (95.7) | - |
| Fusidic acid | - | 71 (67.0) | - | - | 14 (60.9) | - |
| Rifampin | - | 106 (100.0) | - | - | 23 (100.0) | - |
| Teicoplanin | - | 105 (99.1) | - | - | 23 (100.0) | - |
| Tetracycline | - | 98 (92.5) | - | - | 23 (100.0) | - |
| Quinupristin/dafopristin | - | 106 (100.0) | - | - | 23 (100.0) | - |
| Nitrofurantoin | - | 105 (99.1) | - | - | 23 (100.0) | - |
| Linezolid | - | 106 (100.0) | - | - | 23 (100.0) | - |
| Telithromycin | - | 106 (100.0) | - | - | 22 (95.7) | - |
| Mupirocin | - | 101 (95.3) | - | - | 21 (91.3) | - |
| Tigecycline | - | 106 (100.0) | - | - | 23 (100.0) | - |
| Total | 64 (100.0) | 106 (100.0) | 57 (100.0) | 23 (100.0) | ||
Values are presented as number (%).